tiprankstipranks
Advertisement
Advertisement

DE:2YP Stock Latest News

Health Catalyst Earnings Call Highlights Transformation Year
Company AnnouncementsHealth Catalyst Earnings Call Highlights Transformation Year
14d ago
HCAT
Canaccord downgrades Health Catalyst to Hold on transformation risk
PremiumThe Fly
Canaccord downgrades Health Catalyst to Hold on transformation risk
14d ago
HCAT
Health Catalyst downgraded to Hold from Buy at Canaccord
PremiumThe Fly
Health Catalyst downgraded to Hold from Buy at Canaccord
14d ago
HCAT
Health Catalyst price target lowered to $2 from $2.50 at Citi
PremiumThe Fly
Health Catalyst price target lowered to $2 from $2.50 at Citi
24d ago
HCAT
Health Catalyst completes sale of Vitalware for $147M
PremiumThe Fly
Health Catalyst completes sale of Vitalware for $147M
28d ago
HCAT
Health Catalyst sees FY26 revenue $246M-$249M, consensus $266.93M
PremiumThe FlyHealth Catalyst sees FY26 revenue $246M-$249M, consensus $266.93M
28d ago
HCAT
Health Catalyst Sells VitalWare, Refocuses Core Operations
Premium
Company Announcements
Health Catalyst Sells VitalWare, Refocuses Core Operations
28d ago
8K
HCAT
Health Catalyst reports Q2 adjusted EPS 4c, consensus 3c
Premium
The Fly
Health Catalyst reports Q2 adjusted EPS 4c, consensus 3c
28d ago
HCAT
Health Catalyst sees Q3 revenue $55M-$56M, consensus $62.91M
PremiumThe Fly
Health Catalyst sees Q3 revenue $55M-$56M, consensus $62.91M
28d ago
HCAT
Health Catalyst price target raised to $2.50 from $1.75 at Citi
PremiumThe Fly
Health Catalyst price target raised to $2.50 from $1.75 at Citi
1M ago
HCAT
Health Catalyst price target raised to $3 from $2 at Canaccord
PremiumThe Fly
Health Catalyst price target raised to $3 from $2 at Canaccord
1M ago
HCAT
Health Catalyst price target raised to $1.75 from $1 at Wells Fargo
PremiumThe Fly
Health Catalyst price target raised to $1.75 from $1 at Wells Fargo
2M ago
HCAT
Health Catalyst: Vitalware Sale Seen as Value-Creating, Enabling Debt Paydown and Strategic Focus; Buy Rating and $2 Price Target Reiterated
PremiumRatingsHealth Catalyst: Vitalware Sale Seen as Value-Creating, Enabling Debt Paydown and Strategic Focus; Buy Rating and $2 Price Target Reiterated
3M ago
HCAT
Health Catalyst Divests Vitalware to Strengthen Core Focus
Premium
Company Announcements
Health Catalyst Divests Vitalware to Strengthen Core Focus
3M ago
8K
HCAT
Health Catalyst to divest Vitalware to Med-Metrix for $147M in cash
Premium
The Fly
Health Catalyst to divest Vitalware to Med-Metrix for $147M in cash
3M ago
HCAT
Health Catalyst: Buy Rating Reaffirmed as Strategic Transformation Supports Long-Term Growth Despite Near-Term Estimate Cuts
PremiumRatings
Health Catalyst: Buy Rating Reaffirmed as Strategic Transformation Supports Long-Term Growth Despite Near-Term Estimate Cuts
4M ago
HCAT
Health Catalyst Earnings Call Maps Costly Transition
PremiumCompany Announcements
Health Catalyst Earnings Call Maps Costly Transition
4M ago
HCAT
Health Catalyst: Buy Rating Reiterated on Project Nexus Progress, Margin Upside, and Unchanged $2 Price Target
PremiumRatings
Health Catalyst: Buy Rating Reiterated on Project Nexus Progress, Margin Upside, and Unchanged $2 Price Target
4M ago
HCAT
Health Catalyst price target lowered to $1.75 from $2 at Stephens
PremiumThe Fly
Health Catalyst price target lowered to $1.75 from $2 at Stephens
4M ago
HCAT
Health Catalyst reports Q1 adjusted EPS 2c, consensus 1c
PremiumThe FlyHealth Catalyst reports Q1 adjusted EPS 2c, consensus 1c
4M ago
HCAT
Health Catalyst sees Q2 revenue $68M-$70M, consensus $70.47M
Premium
The Fly
Health Catalyst sees Q2 revenue $68M-$70M, consensus $70.47M
4M ago
HCAT
Health Catalyst sees FY26 revenue $260M-$265M, consensus $278.88M
Premium
The Fly
Health Catalyst sees FY26 revenue $260M-$265M, consensus $278.88M
4M ago
HCAT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >